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Background and purpose   Radiotherapy (RT) remains the cor-
nerstone of management of spine metastases (SM), even though 
surgery is a well-established treatment for selected patients. We 
compared the use of RT and surgery in a population-based cohort 
of patients with SM, investigated pre-treatment factors that were 
associated with use of these treatment modalities, and examined 
survival. 
Patients and methods   903 patients in the south-eastern Norway 
who were admitted for RT or surgery for SM for the first time 
during an 18-month period in 2007–2008 were identified and their 
medical records were reviewed. 
Results   The primary treatment was surgery in 58 patients 
and RT in 845 patients, including 704 multiple-fraction (MF) and 
141 single-fraction (SF) RT schedules. 11 of 607 patients with-
out motor impairment (2%) and 47 of 274 patients with motor 
impairment (17%) underwent primary operations. 11 of 58 oper-
ated patients and 244 of 845 irradiated patients died within 2 
months after the start of treatment. 26% of those who received 
multiple-fraction RT or surgery died within 2 months.
Interpretation   Motor impairment was the main indication 
for surgery. Better identification of patients with short survival 
is needed to avoid time-consuming treatment (major surgery and 
long-term RT). 
 
External-beam RT has been the standard treatment for spine 
metastases for decades. The effect of surgical treatment as 
opposed to RT has been widely discussed, but there have 
been few publications comparing these two treatment modali-
ties (Finkelstein et al. 2003, Bauer 2005, Klimo et al. 2005, 
Loblaw et al. 2005, Prasad and Schiff 2005, Abrahm et al. 
2008). Laminectomy without stabilization appears to give no 
benefit compared to RT alone (Young et al. 1980). A prospec-
tive randomized study comparing surgical decompression and 
stabilization followed by RT with RT alone in patients with 
spine metastases (SM) and neurological compromise showed 
that those who underwent surgery regained the ability to walk 
more often and maintained the function longer than patients 
treated with RT alone (Patchell et al. 2005). To our knowl-
edge, no reports comparing surgery and RT with pain relief 
as outcome have been published. In a Canadian population-
based study of malignant spinal cord compression (Loblaw 
et al. 2003), one fifth of those who underwent RT or surgery 
were operated initially, but the pretreatment motor status and 
the indications for surgery were not reported.
Life expectancy for most patients with SM is usually lim-
ited to a few months, but varies from weeks to years (van der 
Linden et al. 2005, Rades et al. 2006, Conway et al. 2007). 
Although pain relief and preservation of function are the pri-
mary aims of the treatment, the choice of treatment modality 
should also be tailored to the expected survival. Major surgical 
treatment for SM is generally not indicated if the patient is 
expected to survive less than 3 months (White et al. 2008). For 
these patients, the single-fraction (SF) RT schedule is prefer-
able as, according to several studies, SF and multiple-fraction 
(MF) RT provide equal palliation for painful bone metasta-
ses (van der Linden et al. 2004, Hartsell et al. 2005, Kaasa 
et al. 2006, Chow et al. 2007, Bruland et al. 2009, Sande et 
al. 2009). A decision-making process on the choice of treat-
ment options should include benefits and complications of 
each treatment modality based on the results of valid clinical 
studies that are not biased by selection (Abrahm et al. 2008). 
Studies on surgery for SM have reported complication rates 
of 20–30% (Finkelstein et al. 2003, Jansson and Bauer 2006), 
while serious complications related to palliative RT have not 
been reported.
 In this retrospective study, we examined the recent use 
of RT and surgery for SM in a population-based cohort of 
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pretreatment factors that were associated with the use of either 
RT or surgery. Furthermore, we calculated the median survival 
after treatment for SM and analyzed the pretreatment factors 
that might affect survival. 
Patients and methods
This retrospective study was carried out in the south-eastern 
region of Norway with a population of 2.6 million inhabit-
ants. All patients with first-time event of either RT or sur-
gery for SM in the cervical, thoracic, or lumbar spine during 
the time period from February 1, 2007 through July 31, 
2008 were identified and included. Exclusion criteria were 
extraskeletal lesions without affecting osseous components 
of the vertebrae, intrathecal lesions, and age below 18 years. 
During the study period, RT was available in 4 hospitals in 
the region. Surgical treatment of patients with SM was avail-
able in 2 hospitals. Although both RT and surgery were avail-
able only in 2 of 5 hospitals, surgery alone in 1 hospital, and 
RT alone in 2 hospitals, a multidisciplinary approach was 
available for all patients by internet transfer of MRI and dis-
cussion between surgical and radiotherapy teams in different 
hospitals. 
For identification of the irradiated patients, the medi-
cal records of all patients with radiation target volume in 
spine were reviewed and checked for eligibility. For oper-
ated patients, the surgical departments’ procedure lists were 
checked and the medical records of those who underwent 
spine surgery for malignancy were reviewed. Only the first 
event of each treatment modality was recorded for each 
patient. For patients with more than one cancer diagnosis, 
only the malignancy with dissemination to the spine was 
recorded. The treatment modality used initially was defined 
as the primary treatment. 
903 patients were included in this study. We also identified, 
but excluded, 7 patients who received vertebroplasty as the 
primary treatment and 98 patients who had at least 1 admis-
sion for RT, vertebroplasty, or surgery for SM before the study 
period. From the medical records we retrieved information 
on age, sex, dwelling place, type of primary cancer, date of 
primary cancer diagnosis and diagnosis of SM, ambulatory 
and neurological status at admission, and the actual treat-
ment modality. We also retrieved routine radiological reports, 
concentrating on the multiplicity of the affected vertebrae. 
Frankel grade, which reflects the degree of motor impairment 
(Frankel et al. 1969), was reconstructed (based on review of 
the medical records) as follows: A—no motor or sensory func-
tion, B—preserved sensation only, no motor function, C—
non-ambulatory, wheel-chair bound but some motor function, 
D—ambulatory, but with neurological symptoms, and E—
normal neurological function. Patients with Frankel grades A, 
B, and C were considered to be non-ambulatory. 23 patients 
were described as walking with aid, but it was impossible to 
distinguish between pain and neurological compromise as 
the principal cause of the impaired ambulatory status. These 
patients were allocated to Frankel grade D. 
RT was applied as high-voltage irradiation with linear accel-
erators. The target volume included the entire affected verte-
brae, the processus transversi and the soft tissue component of 
the lesion as imaged by CT or MRI. The adjoining proximal 
and distal vertebrae were included in the treatment volume. 
Survival status on April 24, 2010 was provided by the 
Nowegian National Registry. 
Statistics
The association between categorical variables was evaluated 
by chi-squared tests (Pearson’s and Fisher’s exact tests as 
appropriate). A binary logistic regression model for multiple 
analysis was used to analyze the significance of pretreatment 
factors for the choice of primary treatment. This statistical 
method can overestimate the prevalence ratio, the presented 
odds ratios, and their confidence intervals, which must there-
fore interpreted with caution. Kaplan-Meier plots and log-
rank tests were used for univariate overall survival analysis. 
The observation time was from the start of RT or surgery to 
death, or for a minimum of 19 months. All p-values reported 
are based on 2-sided tests and a p-value of < 0.05 was consid-
ered statistically significant. We used SPSS software for Win-
dows version 16.0.
Ethics
The study was approved by the Regional Committee for Medi-
cal Research Ethics in Southern Norway. 
Results
The median age of the 903 patients was 69 (19–94) years. 542 
patients (60%) were men, 260 (29%) had prostate cancer, 179 
(20%) had lung cancer, 152 (17%) had breast cancer, 79 had 
myeloma or lymphoma, 40 patients had kidney cancer, and 193 
patients had other cancer diagnoses. 142 (16%) had a solitary 
metastasis in the spine; the others had multiple spine metas-
tases. 12 of 248 patients with prostate cancer (5%), 21 of 131 
patients with breast cancer (14%), 28 of 151 patients with lung 
cancer (16%), 23 of 56 patients with myeloma or lymphoma, 
8 of 23 patients with melanoma, and 11 of 29 patients with 
kidney cancer had a solitary spine metastasis. In 351 patients 
(39%), the metastatic lesions in the spine were diagnosed at 
the time of primary cancer diagnosis, 510 (56%) had no spine 
metastases at the time of primary cancer diagnosis, and for 42 
patients the status was unknown. 845 patients received RT and 
58 patients received surgery as primary treatment. The median 
time from the cancer diagnosis to the first event of RT or sur-
gery was 16 (0–390) months. For the RT group, the median 
time was 17 (0–390) months while for the surgery group the 
median time was 0.4 (0–329) months (p < 0.001). Acta Orthopaedica 2011; 82 (2): 365–371  367
At the start of treatement, 98 patients were non-ambulat-
ing—including 9 patients belonging to Frankel group A, 5 
patients belonging to Frankel group B, and 84 patients belong-
ing to Frankel group C. 176 patients could walk despite a 
minor motor deficit (Frankel D) and 607 patients had no motor 
impairment (Frankel E). The neurological status could not be 
recorded for 22 patients. Motor impairment was related to the 
primary cancer diagnosis (Table 1).
In 46 of 58 operated patients, the surgery was followed by 
RT, while 12 patients did not receive postoperative RT either 
because of complications associated with surgery or because 
of early death. 11 of 845 patients who started RT as primary 
treatment were later operated because of worsening of symp-
toms, 3 before and 8 after RT had been completed.
Radiotherapy
8.0 Gy was used as single-fraction (SF) primary treatment in 
141 patients and multiple- fraction (MF) treatment was used 
in 704 patients. In 1 of 4 RT centers, SF RT was used more fre-
quently. The most frequently used MF schedules were 3.0 Gy 
× 10 in 554 patients, 4.0 Gy × 5 in 33 patients, and 3.0 Gy × 12 
in 13 patients. 94% of the patients completed RT as initially 
scheduled. 73 patients were non-ambulatory (Frankel A–C) 
before the start of RT, 154 were ambulatory with minor motor 
deficit (Frankel D), and 596 patients had no motor impairment 
(Frankel E). 
In the multiple logistic regression model, the type of pri-
mary tumor, age, and motor impairment were associated with 
the use of MF RT as opposed to SF RT (Table 2). 
Surgery 
Motor impairment due to epidural compression was the indi-
Table 1. Motor impairment a at the start of treatment according to 
the primary cancer diagnosis (p < 0.001) b
Primary  Normal  Motor impairment
cancer  motor   Ambulation with   No
diagnosis  status  minor motor deficit  ambulation
  (Frankel E)   (Frankel D)  (Frankel A–C)
Breast   124   18   6 
Prostate  170   55   30 
Lung   117   37   16 
Kidney   30   3   7 
Myeloma/Lymphoma  46   20   12 
Other  120   43   27 
Total  607   176   98
a Motor status was unknown for 22 patients
b Pearson chi-square 2-sided test.
Table 2. Comparison of the use of multiple-fraction (MF) and single-fraction (SF) radiother-
apy (RT) as primary treatment for spinal metastatic disease in 845 patients a
  n   MF   SF   p -value  OR (95% CI)
Primary cancer diagnosis        < 0.001 
 Myeloma/lymphoma  60  56  4    1
  Breast  149  135  14  0.7  0.8 (0.3–3.0)
  Prostate  249  200  49  0.02  0.2 (0.1–0.8)
  Lung  172  128  44  0.002  0.2 (0.1–0.5)
  Kidney  37  34  3  0.5  0.5 (0.1–2.8)
  Other  178  151  27  0.1  0.3 (0.1–1.1)
Age      0.04 
 70+  407  323  84    1
  50–69  375  325  50  0.01  1.8 (1.1–2.8)
  19–49  63  56  7  0.4  1.4 (0.6–3.5)
Sex      0.5 
 Female  345  294  51   
 Male  500  410  90   
Motor impairment b       < 0.001 
  Non-ambulatory (Frankel A–C)  73  69  4    1
  Ambulatory with minor motor 
    deficit (Frankel D)  154  141  13  0.4  0.6 (0.2–1.9)
  Normal motor status (Frankel E)  596  486  110  0.005  0.2 (0.1–0.6)
Multiplicity of spine metastases        0.6 
  One vertebra affected  116  99  17   
  Multiple vertebra  729  605  124   
RT center        < 0.001 
  Center 1  90  47  43    1
  Center 2  429  385  44  < 0.001  8.3 (4.7–14.8)
  Center 3  204  169  35  < 0.001  5.0 (2.7–9.2)
  Center 4  122  103  19  < 0.001  5.4 (2.7–10.9)
OR: odds ratio for choice of MF RT vs. SF RT; 95%CI: 95% confidence interval.
a Binary logistic regression model.
b Motor impairment was unknown for 22 patients.
cation for surgical treatment in 46 of 58 
primarily operated patients, pain was 
the indication in 8 patients, 3 patients 
were operated due to spinal stenosis 
caused by tumor mass (but without 
motor impairment), and in 1 patient 
the need for biopsy was recorded as the 
indication for surgery. Posterior decom-
pression and fixation with pedicle 
screws and rods was the most common 
technique (45 patients); 8 patients 
were operated with posterior decom-
pression without fixation. 5 patients, 
all of them with metastatic lesions in 
the cervical spine, were operated with 
anterior approach and corporectomy. 
The reconstruction after corporectomy 
was done with cage in 2 patients and 
with autolog bone graft in 3 patients. 
5 patients were reoperated due to deep 
infection or mechanical problems with 
fixation fixation of implants  within 2 
months. 
Use of primary surgery vs. radio-
therapy 
Surgical treatment was given to 25 of 
98 non-ambulatory patients, to 22 of 
176 patients with minor motor deficit 
(Frankel D), and to 11 of 607 patients 368  Acta Orthopaedica 2011; 82 (2): 365–371
admission for treatment for SM was 5 (0–48) months (Table 
4). 255 of 903 included patients (28%) died within 2 months 
after start of treatment. Survival after 1 year was 31%. Survival 
depended on primary tumor type, motor impairment prior to 
treatment, multiplicity of metastatic lesions in the spine, time 
from primary cancer diagnosis to admission for SM, and age. 
Presence of spine metastases at the time of cancer diagnosis 
was not a statistically significant predictive factor for survival 
(Figure 1). 
70 of 79 patients with myeloma or lymphoma, 134 of 152 
patients with breast cancer, and 211 of 260 patients with pros-
tate cancer were alive 2 months after treatment. The lowest 
2-month survival was in patients with melanoma (15 of 31 
patients still alive), lung cancer (93 of 179), unknown primary 
site (25 of 45), gastrointestinal cancer (42 of 73), and kidney 
cancer (26 of 40 patients still alive). 
487 of 607 patients (80%) with normal neurological status, 
113 of 176 ambulatory patients (64%) with minor neurologi-
cal compromise (Frankel D), and 45 of 98 non-ambulatory 
patients were alive after 2 months. 84% (119 of 142) of the 
patients with a single lesion in the spine and 70% (529 of 761) 
with multiple lesions survived more than 2 months. 
Table 3. Comparison of the use of surgery and radiotherapy (RT) as primary treatment of 
spinal metastatic disease in 903 patients a
  n   Primary   Primary  p-value   OR (95% CI)
   surgery RT
Primary cancer diagnosis        0.006 
  Myeloma and Lymphoma  79  19   60     1
  Breast  152  3   149   0.1  0.3 (0.1–1.5)
  Prostate  260  11   249   0.008  0.2 (0.1–0.7)
  Lung  179  7   172   < 0.001  0.1 (0.04–0.7)
  Kidney  40  3   37   0.1  0.3 (0.07–1.4)
  Other  193  15   178   0.003  0.2 (0.1–0.6)
Age       0.4 
  70+  433  26   40    1
  50–69  400  25   375   0.2  1.6 (0.8–3.2)
  19–49  70  7   63   0.4  1.7 (0.5–6.0)
Gender       0.03 
  Female  361  16   345    1
  Male  542  42   500   0.03  2.5 (1.1–5.7)
Time from primary cancer diagnosis 
    to treatment for SM b       0.6 
  Within one year  396  40   356     1
  Between one and 5 years  279  11   268   0.2  0.6 (0.3–1.3)
  6 years or more  204  5   199   0.08  0.4 (0.1–1.1)
Motor impairment c       < 0.001 
  Normal motor status (Frankel E)  607  11   596     1
  Ambulating with minor motor 
    deficit (Frankel D)  176  22   154   < 0.001  9 (4–21)
  Non-ambulatory (Frankel A–C)  98  25   73  < 0.001  21 (9–50)
Multiplicity of spine metastases        < 0.001 
  One vertebra affected  142  26   116     1
  Multiple vertebra  761  32   729   < 0.001  0.2 (0.1–0.4)
OR: odds ratio for choice of surgery vs. RT; 95% CI: 95% confidence interval.
a Multiple binary logistic regression model.
b Time from primary cancer diagnosis to treatment for SM was unknown for 24 patients.
c Motor impairment was unknown for 22 patients.
without motor impairment (Frankel 
E) (Table 3). Consequently, 47 of 274 
(17%) first-time admitted patients with 
any grade of motor compromise (Fran-
kel A–D) underwent surgery as primary 
treatment. Primary cancer diagnosis, 
grade of motor impairment, male sex, 
and multiplicity of metastases in the 
spine were associated with the use of 
surgery as opposed to RT in the mul-
tiple binary logistic regression analy-
ses (Table 3). Patients younger than 
50 years appeared to be operated more 
often, but the difference was not statisti-
cally significant. The lowest proportion 
of patients who received primary sur-
gery as opposed to RT was in the group 
of patients with breast cancer (2%), 
while 19 of 79 patients with myeloma 
or lymphoma were operated. Surgery 
was performed as primary treatment 
in 18% of the patients with solitary 
spine metastasis and only in 4% of the 
patients with multiple spine metastases 
(Table 3). There were no statistically 
significant differences in the distribu-
tion of operated patients between surgi-
cal centers regarding diagnoses or indi-
cations for surgery. 
Survival
The median survival after the first 
Table 4. Median survival from start of treatment according to the 
primary cancer diagnosis, motor impairment, multiplicity of metas-
tases in the spine, and age
  n   Median survival,   95% CI
   months
Primary tumor       
 Myeloma/Lymphoma  a   79  – –
 Breast  152  18.8  13.5–24.2
 Prostate  260  7.6  6.0–9.2
 Kidney  40  4.0  2.4–5.6
 Other  193  2.7  2.0–3.4
 Lung  179  2.0  1.7–2.4
Motor impairment b     
  Normal neurological status  607  7.0  5.9–8.2
  Ambulatory with minor 
    motor deficit (Frankel D)  176  3.4  2.2–4.6
 Non-ambulatory  98  1.8  1.2–2.4
Multiplicity in spine       
 Single  142  9.1  5.1–13.1
  Not single  761  4.7  4.1–5.3
Age      
 19–49  70  12.0  3.5–20.6
 50–69  400  5.6  4.4–6.7
 70+  433  4.0  3.2–4.8
All included patients  903  5.1  4.4–5.7
a 42 of 79 patients with myeloma/lymphoma were alive at the follow-up. 
b Motor impairment was unknown for 22 patients.Acta Orthopaedica 2011; 82 (2): 365–371  369
11 of 58 patients who underwent surgery as primary treat-
ment, 185 of 704 of those who received MF RT, and 59 of 141 
of those who received SF RT died within 2 months after the 
start of treatment. Overall survival was better in the surgery 
group—in the patients both with and without motor impair-
ment (Figure 2). 
196 of 255 patients (77%) who died within 2 months after 
the start of treatment underwent either surgery or MF RT, and 
84 of those patients had normal neurological status.
Discussion
Our data on the use of surgery and RT for SM are based on a 
geographically defined patient population, which reduces the 
impact of selection bias in the results presented. The indica-
tions for RT are complex, as RT may be used to target pain 
control in patients with uncomplicated painful vertebral 
metastases and in patients with poor performance status and 
short life expectancy, even in the presence of a motor deficit. 
However, we assume that both local tumor control and pain 
Figure 1. Kaplan-Meier plots with results of log-rank tests of survival related to pretreatment factors. A. Primary tumor (p < 0.001). B. Age (p < 
0.001). C. Motor impairment a (p < 0.001). D. Multiplicity of metastases in spine (p < 0.001). E. Time from diagnosis of cancer to treatment b (p < 
0.001). F. Metastases in spine at the time of primary cancer diagnosis c (p = 0.6).
Figure 2. Kaplan-Meier plots with results of log-rank test of overall survival after surgery and 
radiotherapy (RT) for patients without motor impairment (Frankel E) (panel A; p = 0.03), and for 
patients with motor impairment (Frankel A–D) (panel B; p < 0.001). 
Cumulative survival
Months from start of treatment
 
Cumulative survival
Months from start of treatment  A  B
 
Cumulative survival
Months from start of treatment
 
Cumulative survival
Months from start of treatment
 
Cumulative survival
Months from start of treatment
 
Cumulative survival
Months from start of treatment  
Cumulative survival
Months from start of treatment
 
Cumulative survival
Months from start of treatment
 A
 D
 B
 E
 C
 F370  Acta Orthopaedica 2011; 82 (2): 365–371
were the indications for RT in the majority of patients who 
received RT. 
Clinically significant neural compression and spinal insta-
bility are the most common indications for surgical treatment, 
together with non-response to prior RT (Harrington 1997, 
Tomita et al. 2001). Patients with short life expectancy should 
be identified to avoid time-consuming treatment requir-
ing long hospital stay, such as surgery or MF RT. Our study 
showed that a high percentage of patients who received such 
time-consuming treatment died within 2 months. This may 
be partly explained by clinicians’ inability to reliably identify 
patients who are at considerable risk of dying within just a 
few weeks. Estimation of expected survival is usually based 
on doctors’ clinical experience. However, different scoring 
systems predicting survival for patients with SM have been 
elaborated in order to identify a “no surgery” group (Bauer 
and Wedin 1995, Enkaoua et al. 1997, Tomita et al. 2001, 
van der Linden et al. 2005, Tokuhashi et al. 2005, Leithner 
et al. 2008, White et al. 2008). In these systems, the lowest 
expected survival groups are usually associated with 3–6 
months of expected survival time. However, the problem is 
rather to identify the patients who are likely to die from cancer 
within a few weeks—in order to avoid over-treatment, which 
would make their last weeks unnecessarily difficult (Bauer 
2005). Motor impairment, especially inability to walk, has 
been identified as a factor that is predictive of poor survival 
and—together with performance status—has been used in 
different survival scores (Leithner et al. 2008). Motor impair-
ment is, however, difficult to use in the selection of patients 
for “no surgery”, as this parameter is a main indication for 
surgical treatment. 
Lung cancer as a primary diagnosis has been recognized as 
a prognostic factor for poor survival in both our study and in 
several other studies. However, we found that there was no 
substantial difference in the percentage of primarily operated 
patients with lung cancer and patients with diagnoses associ-
ated with better expected survival, such as breast or prostate 
cancer. This shows that the primary cancer diagnosis as a risk 
factor for poor survival was not always taken in account when 
selecting patients for surgical treatment. 
Myeloma and lymphoma are radiosensitive tumors; how-
ever, a high percentage of patients with these diagnoses were 
operated on. This can be explained by the higher percentage 
of patients with motor impairment in this group, and by better 
survival expectancy. Another explanation might be a more 
rapid development of motor deficits in these patients. Further-
more, bony metastatic lesions from lymphoma and myeloma 
are usually osteolytic, which may give mechanical instability 
and indication for surgery, especially in the case of pathologi-
cal fractures and medulla compression by bony fragments. In 
such cases, RT is often considered less effective than surgery. 
We found no statistically significant differences in the distri-
bution of operated patients between surgical centers regarding 
diagnoses or indications for surgery, but different traditions in 
selecting patients for surgery in different centers could cause 
some bias.
The low percentage of operated patients with breast and 
prostate cancer may be explained by low percentages of non-
ambulatory patients, especially in patients with breast cancer. 
This can be explained by slow growth of the tumors, but also 
by a traditionally better follow-up and early referral for treat-
ment of patients with breast cancer. Furthermore, in addition 
to RT, other non-invasive treatment options such as hormone 
therapy and chemotherapy are efficient treatment options in 
these patients.
Although male sex was associated with more frequent use 
of surgery in the multiple model, this finding should be inter-
preted with caution because of the clear connection between 
patient sex and some cancer diagnoses.
The 3-month survival following surgical treatment that we 
found (72%) is similar to the outcome presented in a popula-
tion-based study from Canada (Finkelstein et al. 2003) (71%). 
In a single-institution study from Sweden (Jansson and Bauer 
2006), a postoperative 90-day survival of 63% was found. We 
assume that the choice of treatment modality within the pallia-
tive framework does not affect survival in each particular case. 
The higher survival in the surgery group that we found most 
likely reflects selection of patients with a better prognosis.
RT was used as primary treatment for the majority of our 
patients, and most patients had MF RT rather than SF RT. There 
is still no consensus about the most appropriate RT schedule 
for SM. Rades et al. (2005) and Kaasa et al. (2006) recom-
mended 1 × 8 Gy for patients with poor predicted survival 
and for pain treatment, and 3 Gy × 10 for other patients. In 
our series, most patients (82%) received MF RT. We expected 
that patients with short survival would predominate in the SF 
group, but even among those who died within 2 months, this 
regime was used in only one third of the cases. The treatment 
time with SF is 1 day, and is preferable for patients with a 
short life expectancy. Better clinical guidelines in the selection 
of patients for RT regimens are needed.
Was the balance between the use of RT or surgery in our 
study population adequate according to the accepted guide-
lines? Many patients with motor compromise have advanced 
disease, poor performance status, multiple levels of cord com-
pression, and short survival, and—consequently—are not can-
didates for surgical treatment. Half of our patients with neuro-
logical impairment who were not operated, but underwent RT, 
died within 2 months. We believe that only patients with motor 
impairment and more than 2 months of expected survival time 
should be considered for surgical treatment. In our study, 121 
patients (13% of all patients) with motor impairment under-
went RT and survived more than 2 months. Some of the 121 
irradiated patients with motor compromise may have benefited 
from operation. However, we assume that the ratio between RT 
and surgery in patients with motor impairment was reasonable.
Only 2% of the patients with Frankel E were operated, and 
possibly more patients in this group could have benefited from Acta Orthopaedica 2011; 82 (2): 365–371  371
surgery. Pain as an indication for surgery in patients with SM 
is, however, controversial. RT has been an established treat-
ment for metastatic bone pain for decades. Prospective studies 
comparing pain relief as outcome after RT and surgery are 
needed. 
The limitation of our study is the retrospective design, 
which made it impossible to obtain reliable data about motor 
function at follow-up. Information on factors that have previ-
ously been shown to be of prognostic value for post-treatment 
survival, such as performance status and presence of visceral 
metastases (van der Linden et al. 2005, Leithner et al. 2008), 
was not available in this study. 
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